The DOI matches its Crossref record.
Antibiotic Susceptibility of Multiply Resistant Pseudomonas aeruginosa Isolatedfrom Patients with Cystic Fibrosis, Including Candidates for Transplantation
Open accessAbstract
Chronic lung disease caused by antibiotic-resistant Pseudomonas aeruginosa in patients with cystic fibrosis (CF) is difficult to treat, especially in those who are lung transplantation candidates. Analysis of antibiotic susceptibility and synergy studies of 1,296 isolates revealed that 172 (13.3%) were multiply resistant (i.e., resistant to two or more classes of anti-Pseudomonas agents). beta-Lactam agents (including imipenem and aztreonam) or aminoglycosides inhibited only 11% of the multiply resistant strains, while ciprofloxacin inhibited 34%. High concentrations of tobramycin and gentamicin (200 micrograms/mL), achievable by aerosol administration, inhibited 95% of isolates and overwhelmed permeability-resistance mechanisms. Antimicrobial pairs tested in checkerboard dilutions of clinically achievable drug concentrations inhibited 75% of the multiply resistant strains. On average, three additive and 2.4 synergistic pairs of antimicrobial agents had activity per strain. Transplantation candidates were older than nontransplantation candidates (P = .034), and isolates from transplantation candidates were less likely to be inhibited by antibiotic combinations (P < .001). Administration of aerosolized aminoglycosides and synergy testing of antimicrobial combinations may represent viable therapeutic options for patients with CF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson, R. L., Burns, J. L., & Ramsey, B. W. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200304-505so · Cited by 1,633
Efflux-mediated antimicrobial resistance
Poole, K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki171 · Cited by 1,082
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05041-11 · Cited by 836
Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations
Flume, P. A., Mogayzel, P. J., Robinson, K. A., Goss, C. H., Rosenblatt, R. L., Kuhn, R. J., Marshall, B. C., & and the Clinical Practice Guidelines for Pulmonary Therapies Committee (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200812-1845pp · Cited by 738
Pseudomonas Aeruginosa Biofilms in Cystic fibrosis
H⊘iby, N., Ciofu, O., & Bjarnsholt, T. (2010) · Future Microbiology · doi:10.2217/fmb.10.125 · Cited by 666
Metadata
- Authors
- Saiman, L., Mehar, F., Niu, W. W., Neu, H. C., Shaw, K. J., Miller, G., & Prince, A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-09-01
- Volume
- 23
- Issue
- 3
- Pages
- 532-537
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2077756665
- Cited by
- 164
- References
- 0
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibiotic Susceptibility of Multiply Resistant Pseudomonas aeruginosa Isolatedfrom Patients with Cystic Fibrosis, Including Candidates for Transplantation. https://app.cochat.ai/papers/10.1093/clinids/23.3.532
- The paper
- Saiman, L., Mehar, F., Niu, W. W., Neu, H. C., Shaw, K. J., Miller, G., & Prince, A. (1996). Antibiotic Susceptibility of Multiply Resistant Pseudomonas aeruginosa Isolatedfrom Patients with Cystic Fibrosis, Including Candidates for Transplantation. Clinical Infectious Diseases. https://doi.org/10.1093/clinids/23.3.532
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.